Your browser is no longer supported. Please, upgrade your browser.
CNS Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.57 Insider Own39.72% Shs Outstand17.09M Perf Week-2.72%
Market Cap44.16M Forward P/E- EPS next Y-0.71 Insider Trans0.00% Shs Float15.23M Perf Month-11.82%
Income-9.50M PEG- EPS next Q-0.12 Inst Own4.60% Short Float1.98% Perf Quarter-47.97%
Sales- P/S- EPS this Y-100.30% Inst Trans5.68% Short Ratio0.88 Perf Half Y-18.64%
Book/sh0.82 P/B2.18 EPS next Y-22.40% ROA-130.30% Target Price- Perf Year-41.69%
Cash/sh0.57 P/C3.15 EPS next 5Y- ROE-145.40% 52W Range1.59 - 4.46 Perf YTD0.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-59.87% Beta-
Dividend %- Quick Ratio8.10 Sales past 5Y- Gross Margin- 52W Low12.58% ATR0.13
Employees3 Current Ratio8.10 Sales Q/Q- Oper. Margin- RSI (14)37.20 Volatility7.25% 6.94%
OptionableNo Debt/Eq0.03 EPS Q/Q-4.90% Profit Margin- Rel Volume0.44 Prev Close1.71
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume340.56K Price1.79
Recom2.00 SMA20-8.09% SMA50-20.08% SMA200-17.64% Volume148,722 Change4.68%
Dec-28-20Downgrade Ladenburg Thalmann Buy → Neutral
Aug-24-20Initiated Ladenburg Thalmann Buy $11
May-14-21 09:05AM  
May-13-21 03:23AM  
May-11-21 08:35AM  
Mar-15-21 09:00AM  
Mar-04-21 09:00AM  
Feb-25-21 09:05AM  
Feb-24-21 07:30AM  
Feb-18-21 01:45PM  
Feb-04-21 11:53AM  
Jan-13-21 08:30AM  
Jan-07-21 08:30AM  
Dec-28-20 08:00AM  
Dec-23-20 08:30AM  
Dec-17-20 04:05PM  
Dec-16-20 08:30AM  
Nov-24-20 08:00AM  
Nov-19-20 08:00AM  
Nov-18-20 08:00AM  
Nov-17-20 08:00AM  
Nov-12-20 08:00AM  
Oct-29-20 08:00AM  
Oct-12-20 08:00AM  
Oct-09-20 08:00AM  
Oct-01-20 08:00AM  
Sep-24-20 08:00AM  
Sep-17-20 08:00AM  
Sep-11-20 08:00AM  
Sep-10-20 09:00AM  
Sep-03-20 08:00AM  
Aug-27-20 08:00AM  
Aug-25-20 08:39AM  
Aug-20-20 08:00AM  
Aug-11-20 08:00AM  
Jul-22-20 08:00AM  
Jul-15-20 08:00AM  
Jul-08-20 08:00AM  
Jun-30-20 08:00AM  
Jun-29-20 08:35AM  
Jun-23-20 08:49AM  
Jun-11-20 08:00AM  
Jun-09-20 08:00AM  
May-28-20 08:00AM  
May-27-20 06:00PM  
May-18-20 08:48AM  
May-11-20 08:00AM  
May-08-20 05:10PM  
May-04-20 07:12PM  
Apr-30-20 08:00AM  
Apr-24-20 03:05AM  
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Downs ChristopherChief Financial OfficerAug 24Buy2.04142,000289,680142,000Aug 25 07:11 PM